SG166100A1 - Novel compounds - Google Patents

Novel compounds

Info

Publication number: SG166100A1
Authority: SG; Singapore
Prior art keywords: novel compounds; compounds; pyriinido; flpyrimidin; csbp
Prior art date: 2005-03-25

Application number

SG201006926-8A

Other languages

English (en)

Inventor

James Francis Callahan

Zehong Wan

Hongxing Yan

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-25

Filing date

2006-03-24

Publication date

2010-11-29

2006-03-24 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2010-11-29 Publication of SG166100A1 publication Critical patent/SG166100A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Cardiology (AREA)
Diabetes (AREA)
Neurology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Transplantation (AREA)
Obesity (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)

SG201006926-8A 2005-03-25 2006-03-24 Novel compounds SG166100A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US66534705P	2005-03-25	2005-03-25

Publications (1)

Publication Number	Publication Date
SG166100A1 true SG166100A1 (en)	2010-11-29

Family

ID=37053936

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG201006926-8A SG166100A1 (en)	2005-03-25	2006-03-24	Novel compounds

Country Status (23)

Country	Link
US (4)	US20090239846A1 (fr)
EP (1)	EP1866311A4 (fr)
JP (1)	JP2008535820A (fr)
KR (1)	KR20080005223A (fr)
CN (1)	CN101184758B (fr)
AP (1)	AP2281A (fr)
AR (1)	AR053450A1 (fr)
AU (1)	AU2006229967B2 (fr)
BR (1)	BRPI0609579A2 (fr)
CA (1)	CA2602546A1 (fr)
EA (1)	EA200702074A1 (fr)
IL (1)	IL185915A0 (fr)
MA (1)	MA29340B1 (fr)
MX (1)	MX2007011883A (fr)
NO (1)	NO20075273L (fr)
NZ (1)	NZ561438A (fr)
PE (2)	PE20061193A1 (fr)
SG (1)	SG166100A1 (fr)
TW (1)	TW200724142A (fr)
UA (1)	UA95230C2 (fr)
UY (1)	UY29439A1 (fr)
WO (1)	WO2006104889A2 (fr)
ZA (1)	ZA200707798B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7235551B2 (en) *	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
KR100850812B1 (ko)	2000-10-23	2008-08-06	스미스클라인 비참 코포레이션	신규 화합물
ES2295553T3 (es)	2002-02-12	2008-04-16	Smithkline Beecham Corporation	Derivados de nicotinamida utiles como inhibidores de p38.
WO2003088972A1 (fr) *	2002-04-19	2003-10-30	Smithkline Beecham Corporation	Nouveaux composes
UY29439A1 (es) *	2005-03-25	2006-10-02	Glaxo Group Ltd	Nuevos compuestos
PE20061351A1 (es)	2005-03-25	2007-01-14	Glaxo Group Ltd	COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
AU2006229995A1 (en) *	2005-03-25	2006-10-05	Glaxo Group Limited	Process for preparing pyrido(2,3-d)pyrimidin-7-one and 3,4-dihydropyrimido(4,5-d)pyrimidin-2(1H)-one derivatives
WO2006110298A2 (fr) *	2005-03-25	2006-10-19	Glaxo Group Limited	Nouveaux composes
US20100069409A1 (en) *	2006-06-16	2010-03-18	Glaxo Group Limited	"novel compounds"
JP2009542818A (ja) *	2006-06-16	2009-12-03	グラクソグループリミテッド	新規化合物
EP2034838A4 (fr) *	2006-06-16	2012-01-04	Glaxo Group Ltd	Nouveaux composés
JP5254999B2 (ja) *	2007-02-09	2013-08-07	ダウアグロサイエンシィズエルエルシー	特定の置換スルフィルイミン類を殺虫性スルホキシイミン類に酸化する方法
EP1992344A1 (fr)	2007-05-18	2008-11-19	Institut Curie	P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
CA2726158A1 (fr) *	2008-06-11	2009-12-17	Dana Farber Cancer Institute	Composes et compositions utiles pour le traitement de la malaria
CN103827118B (zh) *	2011-07-27	2016-03-09	葛兰素集团有限公司	双环嘧啶酮化合物
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
PT3691620T (pt)	2017-10-05	2022-10-06	Fulcrum Therapeutics Inc	Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
CN111961034A (zh) *	2019-05-20	2020-11-20	浙江同源康医药股份有限公司	用作ret激酶抑制剂的化合物及其应用
CN113750095B (zh) *	2021-03-10	2023-07-04	中国医学科学院医药生物技术研究所	含有环丙基骨架的化合物在制备治疗和/或预防冠状病毒感染药物中的应用

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA966134A (en)	1972-05-05	1975-04-15	Haydn W.R. Williams	1,8-naphthyridine compounds
ZA803539B (en)	1979-06-14	1982-01-27	Wellcome Found	Alkoxybenzylrimidines method for their preparation formulation thereof and their use in medicine
GB2064336B (en)	1979-12-06	1984-03-14	Glaxo Group Ltd	Device for dispensing medicaments
US4353656A (en)	1980-10-14	1982-10-12	Xerox Corporation	Moving coil, multiple energy print hammer system including a closed loop servo
DE3274065D1 (de)	1981-07-08	1986-12-11	Draco Ab	Powder inhalator
WO1983002613A1 (fr)	1981-07-20	1983-08-04	Sallmann, Alfred	Composes oxazoiques a triple substitution
GB2169265B (en)	1982-10-08	1987-08-12	Glaxo Group Ltd	Pack for medicament
US4778054A (en)	1982-10-08	1988-10-18	Glaxo Group Limited	Pack for administering medicaments to patients
LU85034A1 (fr)	1982-10-08	1985-06-19	Glaxo Group Ltd	Dispositifs en vue d'administrer des medicaments a des patients
JPS60226882A (ja)	1984-04-24	1985-11-12	Nippon Zoki Pharmaceut Co Ltd	新規ピリミドピリミジン誘導体
US4560691A (en)	1984-07-13	1985-12-24	Sterling Drug Inc.	5-(Phenyl)-1,6-naphthyridin-2(1H)-ones, their cardiotonic use and preparation
GB2178965B (en)	1985-07-30	1988-08-03	Glaxo Group Ltd	Devices for administering medicaments to patients
AU598093B2 (en)	1987-02-07	1990-06-14	Wellcome Foundation Limited, The	Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof
JPH01261306A (ja)	1988-04-13	1989-10-18	Nippon Kayaku Co Ltd	２−アルキルチオ−４−アミノピリミジン誘導体を有効成分とする開花促進剤
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
IE913473A1 (en)	1990-10-15	1992-04-22	Fujisawa Pharmaceutical Co	Quinazoline derivatives and their preparation
WO1992012154A1 (fr)	1990-12-31	1992-07-23	Fujisawa Pharmaceutical Co., Ltd.	Derive d'immidazotriazine
EP0584222B1 (fr)	1991-05-10	1997-10-08	Rhone-Poulenc Rorer International (Holdings) Inc.	Composes aryle et heteroaryle bis monocycliques et/ou bicycliques qui inhibent la tyrosine kinase d'un recepteur du egf et/ou du pdgf
IL102764A0 (en)	1991-08-16	1993-01-31	Merck & Co Inc	Quinazoline derivatives,and pharmaceutical compositions containing them
DE4131029A1 (de)	1991-09-18	1993-07-29	Basf Ag	Substituierte pyrido (2,3-d) pyrimidine als antidots
GB9127376D0 (en)	1991-12-24	1992-02-19	Wellcome Found	Amidino derivatives
GB9303993D0 (en)	1993-02-26	1993-04-14	Fujisawa Pharmaceutical Co	New heterocyclic derivatives
US5466692A (en)	1993-03-24	1995-11-14	American Home Products Corporation	Substituted pyridopyrimidines and antihypertensives
US5426110A (en)	1993-10-06	1995-06-20	Eli Lilly And Company	Pyrimidinyl-glutamic acid derivatives
GB9325217D0 (en)	1993-12-09	1994-02-09	Zeneca Ltd	Pyrimidine derivatives
IL112249A (en)	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5547954A (en)	1994-05-26	1996-08-20	Fmc Corporation	2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides
TW530047B (en)	1994-06-08	2003-05-01	Pfizer	Corticotropin releasing factor antagonists
ATE229001T1 (de)	1994-06-15	2002-12-15	Wellcome Found	Zwischenprodukte verwendbar in der herstellung von enzym-inhibitoren
KR970705562A (ko)	1994-08-29	1997-10-09	오노다 마사요시	신규한 나프티리딘 유도체 및 이의 의약 조성물(Novel naphthyridine derivatives and medicinal composition thereof)
IL115256A0 (en)	1994-11-14	1995-12-31	Warner Lambert Co	6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
EP0870699A3 (fr)	1995-03-10	1998-10-21	Minnesota Mining And Manufacturing Company	Valve pour bombes aérosol
US5620981A (en)	1995-05-03	1997-04-15	Warner-Lambert Company	Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
US5760220A (en)	1995-06-07	1998-06-02	American Home Products Corporation	Process for preparation of biphenyl derivatives
US5767097A (en)	1996-01-23	1998-06-16	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
DE69718306D1 (de)	1996-04-12	2003-02-13	Sumitomo Pharma	Piperidinylpyrimidine derivate
ZA973884B (en)	1996-05-23	1998-11-06	Du Pont Merck Pharma	Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
US6875769B2 (en)	1996-05-23	2005-04-05	Pfizer Inc.	Substituted6,6-hetero-bicyclicderivatives
ATE232863T1 (de)	1996-08-06	2003-03-15	Pfizer	Substituierte pyrido- oder pyrimidogruppen enthaltende 6,6- oder 6,7-bicyclische derivate
TW477787B (en)	1996-08-27	2002-03-01	Pfizer	Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
US6509320B1 (en)	1996-10-16	2003-01-21	Icn Pharmaceuticals, Inc.	Purine L-nucleosides, analogs and uses thereof
US6147080A (en)	1996-12-18	2000-11-14	Vertex Pharmaceuticals Incorporated	Inhibitors of p38
GB9700226D0 (en)	1997-01-08	1997-02-26	Glaxo Group Ltd	Inhalation device
MY117948A (en)	1997-01-13	2004-08-30	Glaxo Group Ltd	Nitride oxide synthase inhibitors.
US6498163B1 (en)	1997-02-05	2002-12-24	Warner-Lambert Company	Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US5945422A (en)	1997-02-05	1999-08-31	Warner-Lambert Company	N-oxides of amino containing pyrido 2,3-D! pyrimidines
ES2301194T3 (es)	1997-02-05	2008-06-16	Warner-Lambert Company Llc	Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
DE19723722A1 (de)	1997-05-30	1998-12-10	Schering Ag	Nichtsteroidale Gestagene
JP2001526230A (ja)	1997-12-19	2001-12-18	スミスクライン・ビーチャム・コーポレイション	ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用
US6506766B1 (en)	1998-02-13	2003-01-14	Abbott Laboratories	Glucocortiocoid-selective antinflammatory agents
CA2321153A1 (fr)	1998-02-17	1999-08-19	Timothy D. Cushing	Antiviraux derives de pyrimidine
JP2000038350A (ja)	1998-05-18	2000-02-08	Yoshitomi Pharmaceut Ind Ltd	糖尿病治療薬
US6248225B1 (en) *	1998-05-26	2001-06-19	Ppg Industries Ohio, Inc.	Process for forming a two-coat electrodeposited composite coating the composite coating and chip resistant electrodeposited coating composition
EE200000706A (et)	1998-05-26	2002-06-17	Warner-Lambert Company	Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
GB9811599D0 (en)	1998-05-30	1998-07-29	Glaxo Group Ltd	Nitric oxide synthase inhibitors
JP2002517486A (ja)	1998-06-12	2002-06-18	バーテックスファーマシューティカルズインコーポレイテッド	ｐ３８のインヒビター
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
WO2000020402A1 (fr)	1998-10-01	2000-04-13	Astrazeneca Ab	Composes chimiques
WO2000023444A1 (fr)	1998-10-21	2000-04-27	Abbott Laboratories	Composes de 4-aminopyrido[2,3-d]pyrimidine a disubstitution 5,7
US6358959B1 (en)	1999-01-26	2002-03-19	Merck & Co., Inc.	Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
HK1043788A1 (zh)	1999-05-04	2002-09-27	American Home Products Corporation	四環黃體酮受體調節劑化合物及方法
CO5180649A1 (es)	1999-09-01	2002-07-30	Abbott Lab	Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
HUP0303363A2 (hu)	1999-09-17	2004-07-28	Abbott Gmbh & Co., Kg	Kináz-inhibitor hatású heterociklusos vegyületek alkalmazása gyógyszerkészítmények előállítására
WO2001042243A2 (fr)	1999-12-08	2001-06-14	Advanced Medicine, Inc.	Inhibiteurs de proteine kinase
US6632666B2 (en)	2000-01-14	2003-10-14	Biolife Solutions, Inc.	Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
AR030044A1 (es)	2000-01-25	2003-08-13	Warner Lambert Co	Pirido (2,3-d ) pirimidin-2,7-diaminas inhibidores de quinasas
HUP0203803A3 (en)	2000-01-27	2004-09-28	Warner Lambert Co	Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
US7235551B2 (en) *	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CA2401368A1 (fr)	2000-03-06	2001-09-27	Warner-Lambert Company	Inhibiteurs de tyrosine kinase a base de 5-alkylpyrido[2,3-d]pyrimidines
WO2002008948A2 (fr) *	2000-07-24	2002-01-31	Vivcom, Inc.	Systeme et procede d'indexation, de recherche, d'identification et de mise en forme de portions de fichiers electroniques multimedia
US7101882B2 (en)	2000-09-29	2006-09-05	Glaxo Group Limited	Morpholin-acetamide derivatives for the treatment of inflammatory diseases
EP1337255A4 (fr)	2000-10-19	2006-01-25	Smithkline Beecham Corp	Utilisation d'inhibiteurs p38 pour le traitement de toux inflammatoire
KR100850812B1 (ko)	2000-10-23	2008-08-06	스미스클라인 비참 코포레이션	신규 화합물
EP1345603A4 (fr)	2000-12-20	2004-09-08	Merck & Co Inc	Agents inhibiteurs de p38 kinase (halo-benzo carbonyl)heterocyclo- fusionnes phenyl
GB0031179D0 (en)	2000-12-21	2001-01-31	Glaxo Group Ltd	Nitric oxide synthase inhibitors
US6484903B2 (en)	2001-01-09	2002-11-26	Riverwood International Corporation	Carton with an improved dispensing feature in combination with a unique handle
PE20030008A1 (es)	2001-06-19	2003-01-22	Bristol Myers Squibb Co	Inhibidores duales de pde 7 y pde 4
WO2003010143A1 (fr)	2001-07-26	2003-02-06	Samsung Electronics Co., Ltd.	Derives de l'acide dialkylhydroxybenzoique contenant des groupes chelateurs de metaux et leurs utilisations therapeutiques
JP4178783B2 (ja)	2001-10-19	2008-11-12	三菱化学株式会社	光学記録媒体
US7019002B2 (en)	2001-12-11	2006-03-28	Pharmacia & Upjohn, S.P.A.	Pyridopyrimidinones derivatives as telomerase inhibitors
WO2003059899A1 (fr)	2002-01-14	2003-07-24	Boehringer Ingelheim Pharmaceuticals, Inc.	Mimetiques de glucocorticoides, procedes de fabrication, preparations pharmaceutiques renfermant ces mimetiques et utilisations
AU2003214879B2 (en)	2002-01-22	2008-02-07	The Regents Of The University Of California	Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
PL218692B1 (pl) *	2002-01-22	2015-01-30	Warner Lambert Co	Podstawiony 2-(pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-on oraz jego zastosowanie do leczenia zaburzenia lub stanu spowodowanego nieprawidłową proliferacją komórek
US7268152B2 (en)	2002-03-26	2007-09-11	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2003082280A1 (fr)	2002-03-26	2003-10-09	Boehringer Ingelheim Pharmaceuticals, Inc.	Mimetiques de glucocorticoiques, procedes de fabrication, compositions pharmaceutiques, et utilisations correspondants
DE10215316C1 (de)	2002-04-02	2003-12-18	Schering Ag	Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
US7282591B2 (en)	2002-04-11	2007-10-16	Merck & Co., Inc.	1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
AU2003232071A1 (en)	2002-05-06	2003-11-17	Genelabs Technologies, Inc.	Nucleoside derivatives for treating hepatitis c virus infection
US7186864B2 (en)	2002-05-29	2007-03-06	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en)	2002-06-06	2006-07-11	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
SI1521733T1 (sl)	2002-07-08	2014-10-30	Pfizer Products Inc.	Modulatorji glukokortikoidnega receptorja
EP1575502B1 (fr)	2002-07-18	2010-01-20	Bristol-Myers Squibb Company	Compositions et procedes impliquant le site ii des recepteurs nucleaires d'hormones (nhr)
US6995181B2 (en)	2002-07-18	2006-02-07	Bristol-Myers Squibb Co.	Modulators of the glucocorticoid receptor and method
ATE403648T1 (de)	2002-08-21	2008-08-15	Boehringer Ingelheim Pharma	Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung
WO2004026248A2 (fr)	2002-09-20	2004-04-01	Merck & Co., Inc.	Derives d'octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide en tant que modulateurs selectifs de recepteur glucocorticoide
WO2004043367A2 (fr)	2002-11-06	2004-05-27	Bristol-Myers Squibb Company	Composes heterocycliques fusionnes et leur utilisation
JP2004203751A (ja)	2002-12-24	2004-07-22	Pfizer Inc	置換６，６−ヘテロ二環式誘導体
JP2006516561A (ja)	2003-01-17	2006-07-06	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
CA2515939A1 (fr)	2003-02-14	2004-09-02	Smithkline Beecham Corporation	Nouveaux composes
US7138412B2 (en)	2003-03-11	2006-11-21	Bristol-Myers Squibb Company	Tetrahydroquinoline derivatives useful as serine protease inhibitors
EP1636195A1 (fr)	2003-05-27	2006-03-22	Pfizer Products Inc.	Quinazolines et pyrido 3,4-d] pyrimidines utilises comme inhibiteurs de recepteurs tyrosine kinase
TWI220897B (en) *	2003-07-22	2004-09-11	Benq Corp	Recording media feeding system and method
KR20060118398A (ko)	2003-08-05	2006-11-23	버텍스 파마슈티칼스 인코포레이티드	전압 개폐 이온 채널 억제제로서의 축합 피라미딘 화합물
US7098222B2 (en)	2004-05-12	2006-08-29	Abbott Laboratories	Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
WO2006039469A1 (fr) *	2004-09-29	2006-04-13	Graphic Packaging International, Inc	Boite en carton avec distributeur possedant des elements d'acces
JP5111113B2 (ja) *	2004-12-13	2012-12-26	サネシスファーマシューティカルズ，インコーポレイテッド	Ｒａｆキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン
UY29439A1 (es) *	2005-03-25	2006-10-02	Glaxo Group Ltd	Nuevos compuestos
WO2006110298A2 (fr)	2005-03-25	2006-10-19	Glaxo Group Limited	Nouveaux composes
AU2006229995A1 (en) *	2005-03-25	2006-10-05	Glaxo Group Limited	Process for preparing pyrido(2,3-d)pyrimidin-7-one and 3,4-dihydropyrimido(4,5-d)pyrimidin-2(1H)-one derivatives
PE20061351A1 (es) *	2005-03-25	2007-01-14	Glaxo Group Ltd	COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38

2006
- 2006-03-23 UY UY29439A patent/UY29439A1/es unknown
- 2006-03-23 TW TW095109982A patent/TW200724142A/zh unknown
- 2006-03-23 PE PE2006000331A patent/PE20061193A1/es not_active Application Discontinuation
- 2006-03-23 AR ARP060101148A patent/AR053450A1/es not_active Application Discontinuation
- 2006-03-23 PE PE2010000198A patent/PE20100741A1/es not_active Application Discontinuation
- 2006-03-24 EA EA200702074A patent/EA200702074A1/ru unknown
- 2006-03-24 MX MX2007011883A patent/MX2007011883A/es active IP Right Grant
- 2006-03-24 NZ NZ561438A patent/NZ561438A/en not_active IP Right Cessation
- 2006-03-24 US US11/908,435 patent/US20090239846A1/en not_active Abandoned
- 2006-03-24 CN CN2006800183985A patent/CN101184758B/zh not_active Expired - Fee Related
- 2006-03-24 WO PCT/US2006/010792 patent/WO2006104889A2/fr not_active Ceased
- 2006-03-24 CA CA002602546A patent/CA2602546A1/fr not_active Abandoned
- 2006-03-24 BR BRPI0609579-8A patent/BRPI0609579A2/pt not_active IP Right Cessation
- 2006-03-24 AP AP2007004171A patent/AP2281A/xx active
- 2006-03-24 AU AU2006229967A patent/AU2006229967B2/en not_active Ceased
- 2006-03-24 KR KR1020077024433A patent/KR20080005223A/ko not_active Ceased
- 2006-03-24 JP JP2008503226A patent/JP2008535820A/ja active Pending
- 2006-03-24 SG SG201006926-8A patent/SG166100A1/en unknown
- 2006-03-24 EP EP06748656A patent/EP1866311A4/fr not_active Withdrawn
- 2006-03-24 UA UAA200710644A patent/UA95230C2/ru unknown
- 2006-03-24 US US11/389,112 patent/US7674789B2/en not_active Expired - Fee Related
2007
- 2007-09-11 IL IL185915A patent/IL185915A0/en unknown
- 2007-09-12 ZA ZA200707798A patent/ZA200707798B/xx unknown
- 2007-09-24 MA MA30236A patent/MA29340B1/fr unknown
- 2007-10-15 NO NO20075273A patent/NO20075273L/no not_active Application Discontinuation
2009
- 2009-11-16 US US12/618,933 patent/US20100093766A1/en not_active Abandoned
- 2009-11-16 US US12/618,927 patent/US20100093765A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MA29340B1 (fr)	2008-03-03
AP2281A (en)	2011-10-31
WO2006104889A3 (fr)	2007-04-12
US7674789B2 (en)	2010-03-09
US20090239846A1 (en)	2009-09-24
BRPI0609579A2 (pt)	2010-04-20
AU2006229967B2 (en)	2012-02-09
US20100093765A1 (en)	2010-04-15
US20100093766A1 (en)	2010-04-15
WO2006104889A2 (fr)	2006-10-05
UA95230C2 (ru)	2011-07-25
NZ561438A (en)	2011-02-25
UY29439A1 (es)	2006-10-02
EA200702074A1 (ru)	2008-02-28
MX2007011883A (es)	2007-11-13
EP1866311A4 (fr)	2010-03-31
AP2007004171A0 (en)	2007-10-31
NO20075273L (no)	2007-12-12
CN101184758B (zh)	2012-05-02
JP2008535820A (ja)	2008-09-04
ZA200707798B (en)	2009-08-26
EP1866311A2 (fr)	2007-12-19
TW200724142A (en)	2007-07-01
AR053450A1 (es)	2007-05-09
CA2602546A1 (fr)	2006-10-05
AU2006229967A1 (en)	2006-10-05
US20060235030A1 (en)	2006-10-19
PE20100741A1 (es)	2010-11-25
KR20080005223A (ko)	2008-01-10
CN101184758A (zh)	2008-05-21
PE20061193A1 (es)	2006-12-02
IL185915A0 (en)	2008-01-06

Publication	Publication Date	Title
HUS2100051I1 (hu)	2021-12-28	Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
SG166100A1 (en)	2010-11-29	Novel compounds
WO2007147103A3 (fr)	2008-11-13	Nouveaux composés
TW200618800A (en)	2006-06-16	Heterocyclic compounds
NO20075275L (no)	2007-12-27	Nye forbindelser
IL181421A0 (en)	2007-07-04	2,4-di(aminophenyl) pyrimidines as plk inhibitors
MY153727A (en)	2015-03-13	Pyridazinone derivatives
ZA200701137B (en)	2008-11-26	Triazolophthalazines
TW200728277A (en)	2007-08-01	Bicyclic derivatives as P38 inhibitors
MY155719A (en)	2015-11-30	2-benzylpyridazinone derivatives as met kinase inhibitors
WO2007147109A3 (fr)	2008-11-13	Nouveaux composés
MX2007005932A (es)	2007-06-20	1-alquinil-2-ariloxialquilamidas y su uso como fungicidas.
MX2009002842A (es)	2009-05-27	Inhibidores heterociclicos de c-met y usos de los mismos.
DE502008001158D1 (en)	2010-09-30	Benzimidazolderivate
IL205696A0 (en)	2010-11-30	Heterocyclic derivatives, compositions comprising the same and uses thereof
MX2010002245A (es)	2010-03-17	Derivados de ariloxiacetamida bi o triciclicos, saturados e insaturados y su uso como fungicidas.
IL164606A0 (en)	2005-12-18	Novel compounds
TW200716622A (en)	2007-05-01	Substituted piperidines
ZA200801332B (en)	2009-10-28	Pentacyclic kinase inhibitors
TW200700064A (en)	2007-01-01	Novel compounds
WO2007120333A3 (fr)	2008-01-10	Inhibiteurs de kinase tétracycliques
TNSN07241A1 (en)	2008-11-21	Substituted pyrroles, compositions containing same, method for making same and use thereof
MX2009013126A (es)	2010-01-15	Nuevos compuestos 892.
WO2005097755A3 (fr)	2006-03-09	Derives d'imidazol
TW200745115A (en)	2007-12-16	7-Amino-6-heteroaryl-1,2,4-triazolo[1,5-a]pyrimidine compounds and their use for controlling harmful fungi